AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie level 3 Rollforward — Change in Fair Value Recognized in Earnings ($M) ($M)
Form 10-Q / 10-K Fair Value Measurements Note
Latest, Q2 2026
1,518
Period ended Jun 30, 2026
Change on a year earlier
-45.7%
2,795 in Q2 2025
History
43 quarters
Since Q4 2015
Sources
26
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Level 3 Rollforward — Change in Fair Value Recognized in Earnings ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 1,518 | -45.7% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2026 | Mar 31, 2026 | 2,387 | +57.2% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 1,406 | +403.9% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 776 | -42.8% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 2,795 | +89.4% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,518 | +130.0% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2024 | Dec 31, 2024 | 279 | -83.5% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,356 | +16,850.0% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,476 | -4.9% | Form 10-Q (filed 2025-08-04) ↗ |
| Q1 2024 | Mar 31, 2024 | 660 | -64.7% | Form 10-Q (filed 2025-05-09) ↗ |
| Q4 2023 | Dec 31, 2023 | 1,696 | -19.8% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2023 | Sep 30, 2023 | 8 | -103.7% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2023 | Jun 30, 2023 | 1,552 | -3.5% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 1,872 | -350.3% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 2,114 | +811.2% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2022 | Sep 30, 2022 | -214 | -318.4% | Form 10-Q (filed 2023-11-06) ↗ |
| Q2 2022 | Jun 30, 2022 | 1,609 | -40.2% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2022 | Mar 31, 2022 | -748 | +118.1% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2021 | Dec 31, 2021 | 232 | -95.1% | Form 10-K (filed 2024-02-20) ↗ |
| Q3 2021 | Sep 30, 2021 | 98 | -50.3% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 2,692 | +232.8% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | -343 | -576.4% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 4,700 | +973.1% | Form 10-K (filed 2021-02-19) ↗ |
| Q3 2020 | Sep 30, 2020 | 197 | +8.2% | Form 10-Q (filed 2021-11-02) ↗ |
| Q2 2020 | Jun 30, 2020 | 809 | -64.8% | Form 10-Q (filed 2021-08-02) ↗ |
| Q1 2020 | Mar 31, 2020 | 72 | -57.4% | Form 10-Q (filed 2021-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 438 | -216.8% | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2019 | Sep 30, 2019 | 182 | +91.6% | Form 10-K (filed 2020-02-21) ↗ |
| Q2 2019 | Jun 30, 2019 | 2,300 | +374.2% | Form 10-K (filed 2020-02-21) ↗ |
| Q1 2019 | Mar 31, 2019 | 169 | -214.2% | Form 10-Q (filed 2020-05-08) ↗ |
| Q4 2018 | Dec 31, 2018 | -375 | -574.7% | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2018 | Sep 30, 2018 | 95 | -76.3% | Form 10-K (filed 2020-02-21) ↗ |
| Q2 2018 | Jun 30, 2018 | 485 | +695.1% | Form 10-K (filed 2020-02-21) ↗ |
| Q1 2018 | Mar 31, 2018 | -148 | -276.2% | Form 10-K (filed 2020-02-21) ↗ |
| Q4 2017 | Dec 31, 2017 | 79 | -7.1% | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2017 | Sep 30, 2017 | 401 | +285.6% | Form 10-K (filed 2019-02-27) ↗ |
| Q2 2017 | Jun 30, 2017 | 61 | +48.8% | Form 10-K (filed 2019-02-27) ↗ |
| Q1 2017 | Mar 31, 2017 | 84 | – | Form 10-K (filed 2019-02-27) ↗ |
| Q4 2016 | Dec 31, 2016 | 85 | – | Form 10-K (filed 2018-02-16) ↗ |
| Q3 2016 | Sep 30, 2016 | 104 | – | Form 10-K (filed 2018-02-16) ↗ |
| Q2 2016 | Jun 30, 2016 | 41 | – | 10-Q FY2016 (XBRL) ↗ |
| Q1 2016 | Mar 31, 2016 | 0 | – | 10-Q FY2016 (XBRL) ↗ |
| Q4 2015 | Dec 31, 2015 | 0 | – | Form 10-K (filed 2018-02-16) ↗ |
Cite this data
StockData. (2026). AbbVie Level 3 Rollforward — Change in Fair Value Recognized in Earnings ($M) ($M), quarterly Q4 2015–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/cc_fv_change
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.